Percheron raises $2.3m to fully fund clinical trial in AML
Filed with ASX · · 3 pages · English
Summary by 6ix AI
Percheron Therapeutics Limited has announced an institutional placement to raise funds for a clinical trial in acute myeloid leukaemia. Chair Dr. Charmaine Gittleson expressed gratitude to investors for their support in executing this placement at a premium price. The new shares and options will be issued in multiple tranches, pending shareholder approval at the upcoming annual general meeting.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Percheron Therapeutics Limited on 6ix
In the deck
Earlier from Percheron Therapeutics
- Proposed issue of securities - PER
- Initial Director's Interest Notice
- Transitional appointment of Executive Director
- Change of Director's Interest Notice
- Notification of cessation of securities - PER
Later from Percheron Therapeutics
- Percheron Therapeutics Limited Corporate Presentation
- 2026 Notice of Annual General Meeting
- Application for quotation of securities - PER
- Notice under S708A
- Dr Michael Baker Commences as CEO and MD
Follow Percheron Therapeutics into a list and get an email when it puts out news.
Follow Percheron Therapeutics